Navigation Links
Roxane Laboratories, Inc. Announces the New Drug Application Approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL)
Date:1/26/2010

COLUMBUS, Ohio, Jan. 26 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the New Drug Application (NDA) approval of Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL bottles as of January 25th, 2010 by the Food and Drug Administration. This product is indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate.

Roxane Laboratories', Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) is the only FDA approved Morphine Sulfate Oral Solution CII available at this concentration. Roxane Laboratories, Inc. has sufficient supply to meet the entire market demand and no shortage is anticipated. Roxane Laboratories, Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL), will be transitioning to new packaging, labeling, and NDC numbers in the near future. In the mean time, please continue to use the following Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) NDC numbers:

NDC 0054-0352-44 Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL Bottle

NDC 0054-0352-50 Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 120mL Bottle

Roxane Laboratories, Inc. Morphine Sulfate Oral Solution CII, 100mg/5mL (20mg/mL) 30mL and 120mL is available for immediate shipment to wholesalers and pharmacies nationwide.

Full prescribing information for Morphine Sulfate Oral Solution CII is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories, Inc. is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories, Inc. markets more than 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17.0 billion (euro 11.6 billion) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

SOURCE Roxane Laboratories, Inc.

RELATED LINKS
http://www.Roxane.com

'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
7. Roxane Laboratories, Inc. Initiates a Nationwide Voluntary Recall of Two Manufacturing Lots of Sodium Polystyrene Sulfonate Suspension in the US and Puerto Rico
8. Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution
9. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
10. Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in Houston, ... contaminated well water throughout the Houston area. , Heavy floodwaters have led to destroyed ... to contaminants. Residents may not even be aware of the contamination of their water ...
(Date:5/24/2016)... Los Angeles, California (PRWEB) , ... May 24, 2016 , ... ... donated $4,000, food, clothing, supplies and other necessities to Eunime Orphanage in Tijuana, Mexico ... eat pizza and play games at Peter Piper Pizza. , More than 15 ...
(Date:5/24/2016)... ... May 24, 2016 , ... Global Lyme Alliance (GLA), a ... that it has named Scott Santarella as its new CEO. , Santarella ... (ALCF) in San Francisco, where he successfully helped to grow the organization from ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in ... tick bites and how to avoid being bitten this spring. , The official ... , Ticks, small spider-like insects, are known for attaching themselves to their prey while ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications such as ... are widely used for cell and protein analysis. Keeping updated on practical considerations ... efficiency in these areas. , LabRoots introduces a new complementary interactive virtual ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... , May 20, 2016 ... Review, H1 2016" market research report with comprehensive ... (Psoriasis Vulgaris), complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ...
(Date:5/19/2016)... Cellvizio Highlighted in Physician Presentations and ... 91 st Congress of the Japan Gastroenterological ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... Cellvizio platform is being highlighted at two major ... of May. The first meeting highlighting Cellvizio is ...
(Date:5/19/2016)... 2016 According to a new market research ... (U.S., Germany , France , ... and Japan )", published by MarketsandMarkets, The market ... CAGR of 13.9% from 2016 to 2021.      (Logo: ... data Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology: